FDA passes enzalutamide (Xtandi®) For Treatment Of An Advanced Cancer

The US Food and Drug Administration (FDA) has approved a product known as enzalutamide (Xtandi®) to be used in a new way. The body, after an in-depth review says that it is ideal for handling a condition called prostate cancer (mHSPC).

A close outlook

Sometime back, the company gave its approval to the product for the treatment of the non-metastatic castration-resistant form of prostate cancer (nmCRPC). At the same time, it also deemed it fit for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

Charles Sawyers, who happens to be both a scientist and physician for prostate cancer, worked on the enzalutamide synthesis. He partnered with Michael Jung, who happens to be a chemist, and this was at UCLA. The whole undertaking was funded by PCF.

The term mHSPC is commonly used to refer to the section of men suffering severely from prostate cancer. The cancer is usually at a more advanced stage affecting parts outside the gland. It is an adverse condition that is made worse by some testosterone-lowering agents that impact the health of men adversely.

The term would also be appropriate when referring to those men that have had surgery before. It may also be those that have been exposed to radiation, and the condition keeps recurring.

State of affairs

Every year, patients walk to hospitals only to be diagnosed with metastatic conditions. It is a form of treatment that is quite expensive to treat based on the technology and expertise required.

There is also a group of patients who happen to be pretty hormone-sensitive in nature. In most cases, these patients are served with androgen deprivation therapy (ADT). However, this is over a particular length of time. Whether or not the cancer of these patients has developed resistance to ADT is a point of concern.

The approval has been given already, and the body outlines that it heavily relied on phase 3 ARCHES clinical trial. This was a randomized study, and it was showcased at the Genitourinary Cancers Symposium this year in an event held in February.

Its publication was at the New England Journal of Medicine, which happens to be one of the most prestigious medical journals.

Leave a comment